The 2′,5′-oligoadenylate (2-5A)/RNase L pathway is one of several enzymatic pathways induced by interferons (IFN), RNase L is a latent endoribonuclease that is activated on its binding by 2-5A and inhibited by the ribonuclease L inhibitor (RLI), We have shown previously by coimmunoprecipitation that RNase L may be associated with a 90-kDa RNA binding protein (RNABP), identified with a monoclonal antibody (mAb) raised against an RNase L complex purified under native conditions on 2-5A-sepharose. Here we confirm, by gelfiltration and pull-down analysis, the association of RNase L and RNABP, and we demonstrate that this association is significantly increased in the presence of 2-5A, Moreover, we found that RNABP protein levels decrease during terminal differentiation in various cell lines but do not vary during vesicular stomatitis virus (VSV) or encephalomyocarditis virus (EMCV) infection or following IFN-alpha/beta treatment. In this latter case, although total cellular RNABP levels do not vary, the amount of RNABP found in the cytoplasm increases in comparison to that found in the nucleus, indicating a cytoplasmic localization of RNABP after IFN-alpha/beta treatment. Finally, we demonstrate the interaction between RNase L and RNABP in intact cells. Microinjection of an mAb against RNABP into HeLa cells inhibits RNase L antiviral activity and partially inhibits the IFN-alpha/beta-induced antiviral activity.
Characterization of RNABP, an RNA binding protein that associates with RNase L
Le Roy, F.; Laskowska, A.; Silhol, M.; Salehzada, T.; Bisbal, C.
Journal of Interferon and Cytokine Research
2000-07 / vol 20 / pages 635-644
antiviral activity; system; viral-rna; 2-5a synthetase; 2-5a-dependent rnase; encephalomyocarditis virus; hela-cells; interferon-treated cells; mediated inhibition; replication